1. Home
  2. ASAN vs NUVB Comparison

ASAN vs NUVB Comparison

Compare ASAN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$7.88

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.72

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASAN
NUVB
Founded
2008
2018
Country
United States
United States
Employees
N/A
298
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ASAN
NUVB
Price
$7.88
$4.72
Analyst Decision
Hold
Strong Buy
Analyst Count
14
8
Target Price
$12.46
$11.38
AVG Volume (30 Days)
6.8M
4.2M
Earning Date
06-02-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
27.93
N/A
EPS
N/A
N/A
Revenue
$790,806,000.00
N/A
Revenue This Year
$10.19
$203.82
Revenue Next Year
$7.91
$58.18
P/E Ratio
N/A
N/A
Revenue Growth
9.25
N/A
52 Week Low
$5.38
$1.57
52 Week High
$15.71
$9.75

Technical Indicators

Market Signals
Indicator
ASAN
NUVB
Relative Strength Index (RSI) 58.90 48.38
Support Level $7.15 $4.07
Resistance Level $8.20 $5.16
Average True Range (ATR) 0.51 0.28
MACD 0.22 0.02
Stochastic Oscillator 59.73 60.94

Price Performance

Historical Comparison
ASAN
NUVB

About ASAN Asana Inc.

Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: